Economic Analysis of Finasteride: A Model-Based Approach Using Data from the Proscar Long-Term Efficacy and Safety Study

    June 1999 in “ Clinical Therapeutics
    Peter C. Albertsen, James M. Pellissier, Franklin C. Lowe, Cynthia J. Girman, Claus G. Roehrborn
    Image of study
    TLDR Finasteride is a cost-effective option for treating BPH, reducing risk of urinary issues and surgery.
    A study using data from the Proscar long-term efficacy and safety study found that finasteride is a cost-effective treatment for benign prostatic hyperplasia (BPH) compared to watchful waiting and terazosin over a 2-year period. Finasteride reduces the risk of acute urinary retention and surgery, resulting in cost savings. The study recommends finasteride as a viable option for BPH treatment.
    Discuss this study in the Community →

    Research cited in this study

    1 / 1 results

    Related Community Posts Join

    6 / 1000+ results

    Related Research

    3 / 3 results